GlassScriptPhysician profile
Robert Taylor Davis
NPI 1295184158
$6,551.16
in general payments reported to CMS, 2019-2025
17 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $1,547 · 2023: $1,558 · 2024: $1,474 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.57 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $2,265.36 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $1,452.91 | 2022-2025 | Xen Glaucoma Treatment System, Alphagan P, Lumigan |
| Bausch & Lomb Americas INC. | $505.09 | 2022-2025 | Vyzulta, Biotrue One Day, Miebo |
| Alcon Vision LLC | $432.80 | 2022-2025 | Clareon, Tryptyr, Rocklatan |
| Allergan, INC. | $405.51 | 2021-2022 | |
| Nova Eye, INC. | $385.46 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $378.33 | 2023-2025 | Tecnis Iol, Tecnis Iol, Veritas Vision System |
| Glaukos Corporation | $204.27 | 2022-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Ocular Therapeutix, INC. | $199.68 | 2024-2025 | Dextenza |
| Astellas Pharma US INC | $54.57 | 2023-2024 | Izervay |
| New World Medical,INC. | $51.10 | 2023-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
| Thea Pharma INC. | $41.74 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.54 | 2021 | |
| Biotissue Holdings INC. | $38.00 | 2025 | |
| Rayner Intraocular Lenses Limited | $35.99 | 2024-2025 | Omidria, Rayone Aspheric, Rayone Spheric |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.69 | 2022 | |
| Genentech USA, INC. | $25.12 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.